Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

In collaboration with EuroIntervention Journal

The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...

Mirvat Al Asnag reports live on three late-breaking trials presented at ACC 2019: PARTNER 3, Evolut Low Risk Trial and the Apple Heart Study

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.